Eli Lilly and Company (NYSE: LLY) today announced today (Aug. 3) the initiation of BLAZE-2, a Phase 3 trial studying LY-CoV555 for the prevention of SARS-CoV-2 infection and COVID-19 in residents and staff at long-term care facilities in the U.S. (skilled nursing facilities, commonly referred to as nursing homes, and assisted living facilities), according to […]
The post Release: Lilly Initiates Phase 3 Trial of LY-CoV555 Antibody appeared first on RVBusiness - Breaking RV Industry News.